RET and non-small cell lung carcinoma: Selpercatinib was given to patients with RET fusion-positive non-small cell lung cancer (NSCLC) in the LIBRETTO-001 phase I/II open-label trial (69 patients were treatment naïve, 247 had previously received platinum-based chemotherapy) [81].